4.7 Article

Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 4, 页码 1478-1494

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01688

关键词

-

资金

  1. Intramural Research Programs of the National Institute on Drug Abuse
  2. National Institute of Neurological Disorders and Stroke

向作者/读者索取更多资源

The development of bitopic ligands directed toward D-2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies. The structural similarities between dopamine D-3 receptor (D3R)-selective molecules that display bitopic or allosteric pharmacology and those that are simply competitive antagonists are subtle and intriguing. Herein we synthesized a series of molecules in which the primary and secondary pharmaco-phores were derived from the D3R-selective antagonists SB269,652 (1) and SB277011A (2) whose structural similarity and pharmacological disparity provided the perfect templates for SAR investigation. Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, 18a and 25a, which further delineates SAR associated with allosterism at D3R and provides leads toward novel drug development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

The respiratory depressant effects of mitragynine are limited by its conversion to 7-OH mitragynine

Rob Hill, Andrew C. Kruegel, Jonathan A. Javitch, J. Robert Lane, Meritxell Canals

Summary: The study found differential effects of Mitragynine and its metabolite, 7-OH Mitragynine, on mouse respiration and anti-nociception. Mitragynine showed a ceiling effect on respiratory depression, while 7-OH Mitragynine had dose-dependent effects. Inhibition of CYP3A reduced the respiratory depressant effects and anti-nociception induced by Mitragynine, but had no effect on the effects of 7-OH Mitragynine. These findings suggest that metabolic saturation may contribute to the improved safety profile of Mitragynine.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Meeting Abstract Biochemistry & Molecular Biology

Novel Dopamine D4 Receptor-Selective Antagonists For Neuropsychiatric Disorders

Thomas M. Keck, Shreya Kelshikar, Nisha Shah, Connor McBride, Moises Ximello Sanchez, Diandra Panasis, Brianna Maslonka, Abigail Muccilli, Maria Ladik, Ebrar Akca, Sophia Ginet

FASEB JOURNAL (2022)

Article Biology

OZITX, a pertussis toxin-like protein for occluding inhibitory G protein signalling including Gαz

Alastair C. Keen, Maria Hauge Pedersen, Laura Lemel, Daniel J. Scott, Meritxell Canals, Dene R. Littler, Travis Beddoe, Yuki Ono, Lei Shi, Asuka Inoue, Jonathan A. Javitch, J. Robert Lane

Summary: Understanding the signaling of heterotrimeric G proteins is crucial for understanding physiological responses. Pertussis toxin has been widely used to inhibit G alpha(i/o) G proteins, but its effectiveness against G alpha(z) has been limited. A recently discovered toxin, OZITX, has been found to specifically inhibit both G alpha(i/o) and G alpha(z) G proteins, providing a new tool to study their signaling.

COMMUNICATIONS BIOLOGY (2022)

Review Pharmacology & Pharmacy

Illuminating the monoamine transporters: Fluorescently labelled ligands to study dopamine, serotonin and norepinephrine transporters

Gisela Andrea Camacho-Hernandez, Khorshada Jahan, Amy Hauck Newman

Summary: Fluorescence microscopy has revolutionized the visualization of physiological processes in live-cell systems, and with the recent innovations in super resolution microscopy, these events can be examined with high precision and accuracy. The development of fluorescently labelled small molecules has provided a significant advance in understanding the physiological relevance of targeted proteins that can now be visualized at the cellular level. The study of monoamine transporters (MATs) and their regulation and dysregulation is crucial for treating neuropsychiatric conditions, and the design of fluorescently labelled ligands (FLL) has greatly contributed to advancing our understanding of MATs in health and disease.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2023)

Article Chemistry, Medicinal

Dopamine D3/D2 Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders

Emma S. Gogarnoiu, Caleb D. Vogt, Julie Sanchez, Alessandro Bonifazi, Elizabeth Saab, Anver Basha Shaik, Omar Soler-Cedeno, Guo-Hua Bi, Benjamin Klein, Zheng-Xiong Xi, J. Robert Lane, Amy Hauck Newman

Summary: Highly selective dopamine D3 receptor (D3R) partial agonists/antagonists have not been successful for the treatment of psychostimulant use disorders (PSUD) due to low potency/efficacy or potential cardiotoxicity. This study suggests that moderately selective D3R/D2R partial agonists/antagonists may be effective in treating PSUD and comorbidities with other affective disorders. Cariprazine and its analogues showed promising results in reducing cocaine self-administration in rats.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Pharmacology & Pharmacy

The Effects of the Dopamine Transporter Ligands JJC8-088 and JJC8-091 on Cocaine versus Food Choice in Rhesus MonkeysS

Omeed Rahimi, Jianjing Cao, Jenny Lam, Steven R. Childers, Rana Rais, Linda J. Porrino, Amy Hauck Newman, Michael A. Nader

Summary: Although there are currently no FDA-approved treatments for cocaine use disorder, promising results have been seen with modafinil analogs in reducing cocaine self-administration and reinstatement in rats. This study compared two compounds, JJC8-088 and JJC8-091, in rhesus monkeys and found that JJC8-088 had higher DAT affinity and showed more significant reduction in cocaine choice compared to JJC8-091. These findings suggest the potential for developing pharmacotherapeutics for cocaine use disorder without abuse liability.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

3,4-Methylenedioxypyrovalerone High-Responder Phenotype as a Tool to Evaluate Candidate Medications for Stimulant Use Disorder

Michelle R. Doyle, Lindsey N. Peng, Jianjing Cao, Kenner C. Rice, Amy Hauck Newman, Gregory T. Collins

Summary: Despite years of research, there are currently no FDA-approved medications for treating stimulant use disorders. Preclinical studies have shown that candidate medications can reduce self-administration of stimulants in animals, but this effect is not consistently observed in humans. This may be due to the fact that most preclinical studies do not accurately replicate the dysregulated and/or compulsive drug-taking patterns seen in individuals with stimulant use disorders. However, this study found that drugs targeting dopamine D3 or 5-HT2C receptors can effectively reduce these abnormal drug-taking patterns, highlighting their potential for treating stimulant use disorders.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Review Chemistry, Medicinal

Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders

Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, Alessandro Piergentili, Elizabeth Saab, Luca Botticelli, Carlo Cifani, Emanuela Micioni Di Bonaventura, Maria Vittoria Micioni Di Bonaventura, Wilma Quaglia

Summary: Orexin-A and Orexin-B are highly conserved hypothalamic neuropeptides that mediate their effects through two distinct G protein-coupled receptors, OX1-R and OX2-R. They play important roles in various physiological functions such as sleep-wake cycle regulation, emotion, panic-like behaviors, anxiety/stress, food intake, and energy homeostasis. This review focuses on the medicinal chemistry aspects of small molecules acting as dual or subtype selective OX1-R/OX2-R agonists and antagonists, as well as radiolabeled OX-R ligands for molecular imaging.

MEDICINAL RESEARCH REVIEWS (2023)

Article Neurosciences

Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys

Kendall Woodlief, Mia I. Allen, Jeremy C. Cornelissen, Matthew L. Banks, Amy Hauck Newman, Michael A. Nader

Summary: Recent studies suggest that dopamine D3 receptors (D3R) may be a therapeutic target for opioid use disorders (OUD). This study examined the effects of the D3R partial agonist (+/-)VK4-40 and the D3R-selective antagonist (+/-)VK4-116, compared to the mu-opioid receptor antagonist naltrexone (NTX), in nonhuman primate models of OUD and antinociception. The results suggest that (+/-)VK4-40 may be a novel pharmacotherapy for OUD.

NEUROPSYCHOPHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

An FSCV Study on the Effects of Targeted Typical and Atypical DAT Inhibition on Dopamine Dynamics in the Nucleus Accumbens Shell of Male and Female Mice

Melinda Hersey, Andy Y. Chen, Mattingly K. Bartole, Jayati Anand, Amy Hauck Newman, Gianluigi Tanda

Summary: Understanding the neurochemistry of sex differences in psychostimulant use disorders is crucial for developing effective therapies. This study utilized fast scan cyclic voltammetry to investigate dopamine dynamics in the nucleus accumbens shell of male and female mice. The findings suggest that cocaine has different effects on dopamine clearance and stimulation of the nucleus accumbens in male and female mice. Modafinil and its analogs show potential as therapeutic options for psychostimulant use disorders, with varying effects on dopamine dynamics.

ACS CHEMICAL NEUROSCIENCE (2023)

Article Pharmacology & Pharmacy

Assessment of the potential of novel and classical opioids to induce respiratory depression in mice

Rob Hill, Julie Sanchez, Laura Lemel, Mirjana Antonijevic, Yselkla Hosking, Shailesh N. Mistry, Andrew C. Kruegel, Jonathan A. Javitch, J. Robert Lane, Meritxell Canals

Summary: This study evaluated the effects of three novel opioids on respiratory depression and analgesia, and compared these measurements with their in vitro efficacy. The results showed that these opioids can induce respiratory depression and analgesia at certain doses, but there are differences in potency and duration of effect among the novel opioids.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Chemistry, Medicinal

Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D-3 (D3R) and & mu;-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics

Alessandro Bonifazi, Elizabeth Saab, Julie Sanchez, Antonina L. Nazarova, Saheem A. Zaidi, Khorshada Jahan, Vsevolod Katritch, Meritxell Canals, J. Robert Lane, Amy Hauck Newman

Summary: A new generation of dual-target μ opioid receptor (MOR) agonist/D3R antagonist/partial agonists was designed and synthesized. Through in vitro and in silico screening, new structural scaffolds were identified that achieved high affinity for MOR and D3R, improving receptor subtype selectivity and predicted blood-brain barrier permeability. Lead compounds have the potential for analgesic effects with reduced opioid-misuse liability via D3R antagonism.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Pharmacology & Pharmacy

The neuromedin U system: Pharmacological implications for the treatment of obesity and binge eating behavior

Luca Botticelli, Emanuela Micioni Di Bonaventura, Fabio Del Bello, Gianfabio Giorgioni, Alessandro Piergentili, Wilma Quaglia, Alessandro Bonifazi, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura

Summary: Neuromedin U (NMU) is a bioactive peptide involved in multiple physiological processes, acting through two G protein coupled receptors (GPCR). NMU plays a role in regulating food intake and has anti-obesity properties. It also influences binge eating behavior, suggesting its potential as a therapeutic target for obesity and eating disorders.

PHARMACOLOGICAL RESEARCH (2023)

Article Biochemistry & Molecular Biology

The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor

Alexander Goldberg, Bing Xie, Lei Shi

Summary: The study explores the binding and allosteric mechanisms of LY3154207, an allosteric compound that targets the dopamine D1 receptor. The research provides insights into the role of LY3154207 in stabilizing the receptor structure and inducing changes in key structural motifs, contributing to the understanding of its therapeutic potential as an allosteric modulator.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Chemistry, Medicinal

Highly Potent and Selective Dopamine D4 Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma

Pegi Pavletic, Ana Semeano, Hideaki Yano, Alessandro Bonifazi, Gianfabio Giorgioni, Alessandro Piergentili, Wilma Quaglia, Maria Giovanna Sabbieti, Dimitrios Agas, Giorgio Santoni, Roberto Pallini, Lucia Ricci-Vitiani, Emanuela Sabato, Giulio Vistoli, Fabio Del Bello

Summary: In this paper, new ligands with high affinity and selectivity for D4R were discovered to better understand its role in GBM. The D4R antagonist 24 and biased ligand 29 showed the most potential and induced a decreased viability of GBM cells. Interestingly, these compounds had a greater effect in reducing cell viability compared to temozolomide, the first-choice chemotherapeutic drug in GBM.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

暂无数据